Literature DB >> 17162418

Risk factors and prevention of end stage renal disease in uruguay.

Nelson Mazzuchi1, Emma Schwedt, Laura Solá, Carlota González, Alejandro Ferreiro.   

Abstract

Uruguay is a developing country with a privileged established program for renal replacement therapy (RRT) for all patients with end stage renal disease (ESRD) since 1981. In December 2004, the RRT prevalence reached 916 patients per million population. The ESRD incidence has not changed significantly in the last eight years, differing with what is observed in other countries. In contrast, the ESRD incidence secondary to diabetic nephropathy has shown a permanent increase. The prevention of chronic kidney disease (CKD) began in 1989 with the Program of Prevention and Treatment of Glomerulonephritis (PPTG), being extended in 2002 to all CKD and canalized through the National Program of Renal Healthcare (NPRH) since 2004. The registry of glomerulonephritis has been demonstrated in recent years: patients are referral to nephrologists earlier, there is an increase of the frequency of patients with "clinical remission," and thus there is a decrease of the frequency of ESRD in the first three months after referral. The NPRH has been developed in a progressive way with the involvement of government authorities and the active participation of the nephrologists. A global prevention program, integrating the prevention of CKD, cardiovascular diseases, hypertension, and diabetes was developed. The first steps of the program have had important achievements: a rational reorientation of nephrologic care in the first level of attention, patient access to renoprotective medications without cost; a registration system of patients, the creation of a formal multidisciplinary team, and the instauration of a continuous medical education program.

Entities:  

Mesh:

Year:  2006        PMID: 17162418     DOI: 10.1080/08860220600925677

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

Review 1.  Global case studies for chronic kidney disease/end-stage kidney disease care.

Authors:  Chih-Wei Yang; David C H Harris; Valerie A Luyckx; Masaomi Nangaku; Fan Fan Hou; Guillermo Garcia Garcia; Hasan Abu-Aisha; Abdou Niang; Laura Sola; Sakarn Bunnag; Somchai Eiam-Ong; Kriang Tungsanga; Marie Richards; Nick Richards; Bak Leong Goh; Gavin Dreyer; Rhys Evans; Henry Mzingajira; Ahmed Twahir; Mignon I McCulloch; Curie Ahn; Charlotte Osafo; Hsiang-Hao Hsu; Lianne Barnieh; Jo-Ann Donner; Marcello Tonelli
Journal:  Kidney Int Suppl (2011)       Date:  2020-02-19

2.  International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts.

Authors:  Thomas Dienemann; Naohiko Fujii; Paula Orlandi; Lisa Nessel; Susan L Furth; Wendy E Hoy; Seiichi Matsuo; Gert Mayer; Shona Methven; Franz Schaefer; Elke S Schaeffner; Laura Solá; Bénédicte Stengel; Christoph Wanner; Luxia Zhang; Adeera Levin; Kai-Uwe Eckardt; Harold I Feldman
Journal:  BMC Nephrol       Date:  2016-09-02       Impact factor: 2.388

3.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population.

Authors:  Cai-Mei Zheng; Jia-Yi Wang; Tzu-Ting Chen; Yun-Chun Wu; Yi-Lien Wu; Hsin-Ting Lin; Sheng-Po Chiu; Tian-Jong Chang; Jing-Quan Zheng; Nain-Feng Chu; Yu-Me Lin; Sui-Lung Su; Kuo-Cheng Lu; Jin-Shuen Chen; Fung-Chang Sung; Chien-Te Lee; Yu Yang; Shang-Jyh Hwang; Ming-Cheng Wang; Yung-Ho Hsu; Hung-Yi Chiou; Senyeong Kao; Mei-Yi Wu; Yuh-Feng Lin
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

4.  Mineral and bone disorder and longterm survival in a chronic kidney disease grade 3b-4cohort.

Authors:  Pablo Rios; Ricardo Silvariño; Laura Sola; Alejandro Ferreiro; Verónica Lamadrid; Laura Fajardo; Liliana Gadola
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

5.  Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes.

Authors:  Pablo Rios; Laura Sola; Alejandro Ferreiro; Ricardo Silvariño; Verónica Lamadrid; Laura Ceretta; Liliana Gadola
Journal:  PLoS One       Date:  2022-10-14       Impact factor: 3.752

6.  Mortality in patients on renal replacement therapy and permanent cardiac pacemakers.

Authors:  Gabriel Vanerio; Cristina García; Carlota González; Alejandro Ferreiro
Journal:  Int J Nephrol       Date:  2014-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.